SNY - Sanofi

NYSE - NYSE Delayed Price. Currency in USD
39.94
+0.96 (+2.46%)
At close: 4:03PM EDT
Stock chart is not supported by your current browser
Previous Close38.98
Open40.06
Bid0.00 x 1000
Ask0.00 x 21500
Day's Range39.67 - 40.18
52 Week Range37.43 - 50.65
Volume7,965,682
Avg. Volume1,644,039
Market Cap99.804B
Beta0.83
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.86 (4.64%)
Ex-Dividend Date2018-05-09
1y Target Est44.00
Trade prices are not sourced from all markets
  • 3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry
    InvestorPlace4 days ago

    3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry

    In spite of a strong start in 2018, the pharma/biotech industry is struggling currently, presumably due to a shift in focus to lowering of high drug prices and faster approval of generics. This has led to an increase in merger & acquisition activity and may boost innovation and capital building in the biotech industry. Earlier in the year, we have seen Sanofi SA (NYSE:SNY) and Celgene Corporation (NASDAQ:CELG) acquiring smaller biotech companies.

  • Reuters4 days ago

    Study confirms higher risk of dengue in kids who got Sanofi vaccine

    An analysis of data on Sanofi's dengue vaccine, which has been given to more than 800,000 school children in the Philippines, confirms it increases the risk of hospitalization and severe dengue in those who had never previously been infected with the mosquito-borne virus. The findings, published on Wednesday in the New England Journal of Medicine, offer fresh support for the World Health Organization recommendation in April that Sanofi's vaccine should not be used without testing for prior dengue exposure. Currently, there are no widely available rapid tests for prior dengue infection.

  • Sanofi Plots Cancer Comeback With First New Drug in Years
    Bloomberg5 days ago

    Sanofi Plots Cancer Comeback With First New Drug in Years

    Sanofi was a spectator during the last wave of cancer breakthroughs. The French drugmaker is counting on its first new tumor drug in seven years to help make it a contender in the next one. A treatment Sanofi is developing with Regeneron Pharmaceuticals Inc. could go on sale by the end of the year, said Joanne Lager, head of oncology development at the Paris-based company.

  • Benzinga5 days ago

    Benzinga's Daily Biotech Pulse: vTv Swoons On Failed Alzheimer's Trial, Regenxbio Gets FDA Fast Track For RGX-111

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 12) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...

  • CNW Group5 days ago

    Canadian employers underestimate the proportion of their workforce with a chronic condition and its impact

    TORONTO , June 13, 2018 /CNW Telbec/ - The 21st edition of The Sanofi Canada Healthcare Survey of Canadian employees with workplace health benefit plans (plan members) and of organizations who offer their employees health benefits (plan sponsors) indicates that while 58% of surveyed plan members report having at least one chronic disease or condition, plan sponsors underestimate the proportion of their workforce with a chronic condition (29%). Three-quarters (77%) of plan sponsors indicate they are concerned about the impact of unmanaged chronic disease on the productivity of their workforce.

  • Sanofi says on track to regain solid position in cancer drugs
    Reuters5 days ago

    Sanofi says on track to regain solid position in cancer drugs

    Sanofi (SASY.PA) believes it can make a comeback and re-establish a leading position in the competitive cancer drug market on the back of its immunotherapy drugs and efforts in new areas such as molecular oncology. "We missed the immunology wagon in recent years but we are committed to catching up and we have a significant number of assets," Jorge Insuasty, Sanofi's global head of development, told journalists on Wednesday. Sanofi is working on 10 new cancer medicines.

  • Reuters5 days ago

    Sanofi says on track to regain solid position in cancer drugs

    Sanofi believes it can make a comeback and re-establish a leading position in the competitive cancer drug market on the back of its immunotherapy drugs and efforts in new areas such as molecular oncology. "We missed the immunology wagon in recent years but we are committed to catching up and we have a significant number of assets," Jorge Insuasty, Sanofi's global head of development, told journalists on Wednesday. Sanofi is working on 10 new cancer medicines.

  • GlobeNewswire5 days ago

    Sanofi : Sanofi successfully prices USD 2 billion bond issue

      Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)   Sanofi successfully prices USD 2 billion bond issue     Paris, France - June 13, 2018 - Sanofi has successfully priced its offering of USD 2 ...

  • GlobeNewswire7 days ago

    Sanofi Launches "Action 2018", a Worldwide Employee Stock Purchase Plan

    In doing such a capital increase, Sanofi intends to better associate its employees with the future development and results of the company. On March 6, 2018­ the Board of Directors authorized an issuance of ordinary shares of Sanofi for the benefit of employees participating in the Group Savings Plan. The subscription price is €52.66.

  • GlobeNewswire10 days ago

    Factors of Influence in 2018, Key Indicators and Opportunity within CNH Industrial N.V, Sanofi, New York, Nabors Industries, Aptiv, and PagSeguro Digital — New Research Emphasizes Economic Growth

    NEW YORK, June 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CNH ...

  • The Zacks Analyst Blog Highlights: Mastercard, VMware, Sanofi, Twitter and State Street
    Zacks11 days ago

    The Zacks Analyst Blog Highlights: Mastercard, VMware, Sanofi, Twitter and State Street

    The Zacks Analyst Blog Highlights: Mastercard, VMware, Sanofi, Twitter and State Street

  • Top Research Reports for Mastercard, VMware & Sanofi
    Zacks12 days ago

    Top Research Reports for Mastercard, VMware & Sanofi

    Top Research Reports for Mastercard, VMware & Sanofi

  • ACCESSWIRE12 days ago

    Stock Performance Review on TherapeuticsMD and Three Other Healthcare Stocks

    LONDON, UK / ACCESSWIRE / June 6, 2018 / If you want a free Stock Review on TXMD sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research reports on the following Healthcare stocks: IDEXX Laboratories Inc. (NASDAQ: IDXX), Palatin Technologies Inc. (NYSE AMER: PTN), Sanofi (NYSE: SNY), and TherapeuticsMD Inc. (NASDAQ: TXMD).

  • TheStreet.com12 days ago

    Sanofi, Merck and J&J Tout Lower Drug Prices

    want you to know they dropped drug prices last year. The Food and Drug Administration, meanwhile, has said it plans to cut down on drug monopolies to help others lower their prices too. The moves come after President Trump last month ran out a number of concepts to drive prices down that didn't involve going after drug companies but rather focused on shaming the companies into wanting to decrease medication prices.

  • PR Newswire13 days ago

    New England Journal of Medicine Publishes Cemiplimab Trial Results in Advanced Cutaneous Squamous Cell Carcinoma

    GUILDFORD, England , June 5, 2018 /PRNewswire/ -- - Patients treated with cemiplimab experienced robust anti-tumour effects - Data also presented today at the 2018 ASCO Annual Meeting, - Cemiplimab applications under review by regulatory authorities in the U.S. and ...

  • GlobeNewswire13 days ago

    Sanofi: New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma

      Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)   New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma   ...

  • PR Newswire13 days ago

    New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma

    PARIS and TARRYTOWN, N.Y., June 4, 2018 /PRNewswire/ -- The New England Journal of Medicine (NEJM) today published pivotal data from two trials evaluating cemiplimab in advanced cutaneous squamous cell carcinoma (CSCC). The results were also presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

  • A Short Guide to the Novartis-AveXis Deal
    Market Realist14 days ago

    A Short Guide to the Novartis-AveXis Deal

    On May 15, leading pharmaceutical company Novartis (NVS) acquired AveXis, a US-based clinical-stage gene therapy company. This transaction strengthens Novartis’s position as a leader in gene therapy and neuroscience. The chart below summarizes the deal.

  • Analysts’ Recommendations for GlaxoSmithKline in May
    Market Realist14 days ago

    Analysts’ Recommendations for GlaxoSmithKline in May

    GlaxoSmithKline (GSK) reported EPS of 24.60 British pence on revenue of 7.22 billion pounds, surpassing Wall Street analysts’ consensus estimates of 24.21 pence on revenue of 7.20 billion pounds, in Q1 2018.

  • Why Is Alnylam (ALNY) Up 12.6% Since Its Last Earnings Report?
    Zacks14 days ago

    Why Is Alnylam (ALNY) Up 12.6% Since Its Last Earnings Report?

    Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Why Is Regeneron Pharmaceuticals (REGN) Up 2.7% Since Its Last Earnings Report?
    Zacks14 days ago

    Why Is Regeneron Pharmaceuticals (REGN) Up 2.7% Since Its Last Earnings Report?

    Regeneron Pharmaceuticals (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • The Wall Street Journal16 days ago

    [$$] Sanofi Says Average Net Price of Its Drugs Fell Last Year

    French drug company Sanofi SA says the average price of its medicines fell 8.4% in the U.S. last year after accounting for rebates, the latest example of pharmaceutical pricing pressures. Several major drug companies have now said the net prices of their medicines—that is, the price of the drugs after discounts and rebates—fell in aggregate in 2017. Johnson & Johnson and Merck & Co. have said the sums paid for their drugs had dropped last year, too.

  • Analyzing Novartis’s Revenue in Q1
    Market Realist18 days ago

    Analyzing Novartis’s Revenue in Q1

    In the first quarter, Novartis’s (NVS) revenue grew 10% to ~$12.7 billion from ~$11.5 billion. As we discussed in the previous part, it reported EPS of $1.28, meeting analysts’ estimate. Its revenue of ~$12.7 billion surpassed analysts’ estimate of ~$12.6 billion, marking ~10% YoY (year-over-year) growth.

  • A Look at GlaxoSmithKline’s Valuation on May 29
    Market Realist18 days ago

    A Look at GlaxoSmithKline’s Valuation on May 29

    GlaxoSmithKline (GSK) is focused on maintaining a sustainable growth model by strategizing its business beyond pharmaceuticals.

  • Top Diabetes Stocks to Buy Today
    Motley Fool18 days ago

    Top Diabetes Stocks to Buy Today

    More people than ever are being diagnosed with diabetes, and big advances in treatment could make these diabetes stocks savvy investments.